EP2187874A2 - Compositions à libération prolongée de trimétazidine et procédé de préparation - Google Patents

Compositions à libération prolongée de trimétazidine et procédé de préparation

Info

Publication number
EP2187874A2
EP2187874A2 EP08852448A EP08852448A EP2187874A2 EP 2187874 A2 EP2187874 A2 EP 2187874A2 EP 08852448 A EP08852448 A EP 08852448A EP 08852448 A EP08852448 A EP 08852448A EP 2187874 A2 EP2187874 A2 EP 2187874A2
Authority
EP
European Patent Office
Prior art keywords
composition
weight
trimetazidine
pharmaceutically acceptable
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08852448A
Other languages
German (de)
English (en)
Inventor
Deepak Anant Hegde
Sandhya Rajendra Shenoy
Harish Tulsidutt Bhatt
Ashok Omray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
USV Pvt Ltd
Original Assignee
USV Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by USV Pvt Ltd filed Critical USV Pvt Ltd
Publication of EP2187874A2 publication Critical patent/EP2187874A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising:
  • compositions are in the form of solid dosage forms.
  • the present invention further relates to a process for preparation of said sustained release pharmaceutical compositions.
  • Trimetazidine is used in the treatment of angina pectoris.
  • Trimetazidine dihydrochloride is used therapeutically, as a coronary vasodilator for the prophylactic treatment of anginal chest pain attack and during such attacks, during chorioretinal attacks as well as for the treatment of giddiness of vascular origin.
  • Angina pectoris also known as angina, is chest pain due to ischemia of the heart muscle which inturn is caused due to obstruction or spasm of the coronary arteries.
  • Trimetazidine is chemically l-[(2,3,4-trimethoxyphenyl) methyl]piperazine with molecular formula Q 4 H 22 N 2 O 3 and molecular weight 266.34.
  • Trimetazidine is freely soluble in water. It has two pKa values 4.32 and 8.95. Trimetazidine regulates ionic and extra cellular exchanges, correcting the abnormal flow of ions across the cell membrane caused by ischemia and preventing cellular edema caused by anoxia. Thus it ensures the functioning of the ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
  • Trimetazidine dihydrochloride is administered orally in doses of 40 to 60mg daily in divided doses as an immediate release preparation. It is quickly absorbed and eliminated by the organism with plasma half-life of around 6.0 +/- 1.4 hours and Tmax of around 1.8 +/- 0.7 hours. Since it has a shorter plasma half life, in practice 20mg preparation is given twice or thrice a day in order to ensure relatively constant plasma levels but, due to the fact that it is absorbed quickly, these immediate release forms lead to maximum plasma levels immediately after administration and to a very low plasma level at the time of the next dose, resulting in great differences in peak and trough plasma levels at steady state.
  • Trimetazidine dihydrochloride is regarded as a safe drug in the long-term treatment of chronic ischemic disorders. A need therefore arises for compositions which could provide a sustained effect so as to achieve regular and constant plasma levels and which provides patient compliance.
  • Trimetazidine dihyrochloride There are various marketed preparations containing Trimetazidine.
  • the brand VASTAREL from Sender is also marketed as CARDAPTAN, PREDUCTAL MR, IDAPTAN, FLAVEDON MR, TRIZEDON, VASTINAN and VASOREL.
  • VASTAREL prolonged release film-coated tablets 35 mg contain calcium hydrogen phosphate dihydrate, hypromellose, povidone, anhydrous colloidal silica, magnesium stearate, macrogol, titanium dioxide (E171), glycerol, red iron oxide (E172).
  • US3262852 discloses a vasodilative substance, dihydrochloride of 1 -(2,3,4- trimethoxybenzyl) piperazine i.e. Trimetazidine dihyrochloride.
  • US4814176 discloses a sustained release preparation comprising: (a) chitin, chitosan, or a mixture thereof (b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and (c) pharmaceutically active agents. It however, does not provide any detailed study on Trimetazidine compositions.
  • EP0613686 discloses use of Trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutic use of immuno-suppressants.
  • CNl 864680 discloses orally disintegrated Trimetazidine hydrochloride tablet for treating angina pectoris and its process of preparation.
  • US3950508 discloses delayed action pharmaceutical tablets prepared from admixtures of active ingredient with talc, ethyl cellulose and magnesium stearate as tableting lubricant with twice as much talc present as ethyl cellulose.
  • EP0673649 discloses compositions for prolonged liberation of Trimetazidine (II) or its salts by making use of a mixture of water insoluble polymer and a plasticizer coated on a reservoir to control liberation.
  • EP0673649 discloses compositions containing dose of 80mg of Trimetazidine dihydrochloride which is very high when compared to total conventional dose of 40mg to 60mg, in divided doses.
  • EP 1108424 discloses a matrix tablet for prolonged release of Trimetazidine where the prolonged release is controlled by the use of a cellulose derivative polymer present in the matrix, selected from hydroxypropyl cellulose, hydroxymethyl cellulose, methyl cellulose and hydroxypropyl methyl cellulose.
  • EP 1195160 discloses a pharmaceutical composition for sustained release of Trimetazidine dihydrochloride, comprising Trimetazidine dihydrochloride as the active substance and at least one of: (a) one or more hydrocolloid forming materials; (b) one or more hydrophobic polymers; and (c) one or more other categories of hydrophobic materials.
  • JP61212517 discloses a long-acting tablet of a basic water-soluble medicine, enabling the proper and slow release of the medicine independent to the pH of the gastric or intestinal juice, by using ultra fine powder of an enteric polymer base as a polymeric matrix and using hardened oil as an agent for controlling the release of the medicine.
  • RU2281772 discloses a medicinal formulation where the release of Trimetazidine dihydrochloride in the body from the formulation is carried out for 8 hr that provides the constant level of the preparation in blood.
  • WO02051417 discloses a solid pharmaceutical composition, with controlled release, obtained by hot-process thermoforming of a mixture based on polymers belonging to the polymethacrylate family and Trimetazidine or one of its pharmaceutically acceptable salts.
  • WO03043610 discloses compositions and process for manufacturing of pharmaceutical compositions in the form of microbeads comprising of Trimetazidine dihydrochloride and further coating of the beads with polymeric membrane to tailor the drug release characteristics enabling "once a day” dosing for 60 mg dose of Trimetazidine dihydrochloride per unit dose.
  • the main object of the invention is to provide sustained release pharmaceutical compositions comprising (i) Trimetazidine or a pharmaceutically acceptable salt thereof; (ii) at least one of the release modifying agents selected from; (a) one or more water soluble materials; (b) one or more water insoluble materials; (c) one or more water swellable materials; together with suitable pharmaceutically acceptable excipients.
  • Another object of the invention is to provide pharmaceutical compositions which are characterized by the absence of cellulose and/or their derivatives as release modifying agents.
  • Yet another object of the invention is to provide a process for preparation of sustained release pharmaceutical compositions.
  • compositions which releases Trimetazidine in a sustained and reproducible manner over a prolonged period of time to achieve a sustaining effect of Trimetazidine over 10-12 hours period after oral administration.
  • Further object of the invention is to provide compositions of Trimetazidine that demonstrate reliable release rate and facilitated in-vivo absorption for desired period of time.
  • Another object of the invention is to provide sustained release compositions which are useful for the treatment of angina pectoris and has better patient compliance.
  • Another object of the invention is to provide a method of treating a patient suffering from angina pectoris, comprising administering to a patient in need thereof a therapeutically effective amount of sustained release pharmaceutical compositions as described herein.
  • the present invention discloses sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising Trimetazidine; wherein the compositions are characterized by the absence of cellulose and/or cellulose derivatives as release modifying agents.
  • the present invention provides sustained release pharmaceutical compositions comprising:
  • the present invention provides a process for preparation of sustained release pharmaceutical compositions comprising (i) Trimetazidine or a pharmaceutically acceptable salt thereof; (ii) at least one of the release modifying agents selected from; (a) one or more water soluble materials; (b) one or more water insoluble materials; (c) one or more water swellable materials; together with suitable pharmaceutically acceptable excipients; the said process comprising the steps of : i. preparing an intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii.
  • Fig. 1 shows comparative dissolution profile of Vastarel and tablets prepared according to Example 1. Dissolution was carried out in 0.1N HCL for the first hour and then in pH 6.8 phosphate buffer.
  • Fig. 2 shows comparative dissolution profile of Vastarel and tablets prepared according to Example 2. Dissolution was carried out in 0.1N HCL for the first hour and then in pH 6.8 phosphate buffer.
  • the present invention describes sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising:
  • the present invention further describes a process for preparation of said sustained release pharmaceutical compositions.
  • Sustained release solid dosage forms such as tablets, capsules or any other solid dosage form may be formulated using the process as described herein.
  • compositions of the present invention releases Trimetazidine in a sustained and reproducible manner over a prolonged period of time to achieve a sustaining effect of Trimetazidine over 10-12 hours period after oral administration.
  • the present invention provides sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising Trimetazidine; wherein the compositions are characterized by the absence of cellulose and/or cellulose derivatives as release modifying agents.
  • Trimetazidine is present in an amount from about 8.0% to about 50.0% by weight of the total composition.
  • Trimetazidine is present in an amount from 10.0% to 30.0% by weight of the total composition.
  • the preferred pharmaceutically acceptable salt of Trimetazidine is Trimetazidine dihydrochloride.
  • the release modifying agents may be present in an amount from 10.0% to 80.0% by weight of the total composition.
  • the sustained release pharmaceutical compositions of the present invention comprises release- modifying agents that may be selected from at least one of (a) one or more water- soluble materials and/or (b)one or more water insoluble materials and/or (c) one or more water swellable materials; wherein the said compositions are characterized by the absence of cellulose and/or cellulose derivatives as release modifying agents.
  • the ratio of Trimetazidine to release modifying agents is in the range of about 1:0.5 to 1:10; preferably 1:1 to 1:5.
  • the water soluble materials that may be employed include, but are not limited to polyethylene oxide, sodium alginate, calcium ammonium alginate, potassium alginate, calcium alginate, propylene glycol alginate, polyvinyl alcohol, povidone, carbomer, xanthan gum, triethyl citrate or mixtures thereof.
  • Water-soluble materials may be present in an amount from 10.0% to 80.0% by weight of the total composition.
  • the water- soluble materials may be present in an amount from 15.0% to 70.0% by weight of the total composition.
  • the preferred water soluble materials being polyethylene oxide having average molecular weight 4,00,000 to 60,00,000; more preferably having average molecular weight 6,00,000 to 50,00,000.
  • the water insoluble materials that may be employed include, but are not limited to stearic acid, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, microcrystalline wax, polymethacrylate, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, hydrogenated castor oil, polyvinyl acetate, polyvinyl acetate phthalate, waxes, shellac, magnesium aluminium silicates or mixtures thereof.
  • Kollidone SR a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone is the preferred water insoluble material. Water insoluble materials may be present in an amount from 10.0% to 80.0% by weight of the total composition.
  • the water insoluble materials may be present in an amount from 20.0% to 70.0% by weight of the total composition.
  • the water swellable materials that may be employed include, but are not limited to alginic acid, guar gum or mixtures thereof.
  • Water swellable materials may be present in an amount from 10.0% to 80.0% by weight of the total composition.
  • the water swellable materials may be present in an amount from 20.0% to 70.0% by weight of the total composition.
  • the sustained release compositions of the present invention may contain release modifying agents selected from one or more water soluble material employed together with one or more water insoluble material in a weight ratio of about 10:1 to 1:10.
  • one or more water soluble material may be employed together with one or more water insoluble material in a weight ratio of about 10:5 to 5:10.
  • the sustained release compositions of the present invention may contain release modifying agents selected from one or more water swellable material employed together with one or more water insoluble material in a weight ratio of about 10:1 to 1:10.
  • one or more water swellable material may be employed together with one or more water insoluble material in a weight ratio of about 10:5 to 5:10.
  • Sustained release compositions according to the present invention contain Trimetazidine in a dose range from 20mg to 60mg.
  • the sustained release compositions may contain Trimetazidine in doses such as 35mg, 60mg.
  • Sustained release Trimetazidine compositions having dose of 35mg are recommended for twice-a-day administration in order to achieve a sustained effect of the drug.
  • the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of release modifying agent/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti-adherant and 2.0% to 10.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of water soluble material/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti- adherant and 2.0% to 10.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 15.0% to 70.0% by weight of water soluble material/(s), 20.0% to 60.0% by weight of diluent, 2.0% to 10.0% by weight of binder, 0.1% to 3.0% by weight of lubricant, 0.1% to 3.0% by weight of anti- adherant and 2.0% to 8.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 15.0% to 70.0% by weight of polyethylene oxide, 20.0% to 60.0% by weight of lactose monohydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 8.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 15.0% to 70.0% by weight of xanthan gum, 20.0% to 60.0% by weight of lactose monohydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 8.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of water insoluble material/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti-adherant and 2.0% to 10.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride,20.0% to 70.0% by weight of water insoluble materials), 20.0% to 60.0% by weight of diluent, 2.0% to 10.0% by weight of binder, 0.1% to 3.0% by weight of lubricant, 0.1% to 3.0% by weight of anti- adherant and 2.0% to 8.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 20.0% to 60.% by weight of polymethacrylate, 20.0% to 60.0% by weight of dicalcium phosphate dihydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 7.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of water swellable material/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti-adherant and 2.0% to 10.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 20.0% to 70.0% by weight of water swellable material/(s), 20.0% to 60.0% by weight of diluent, 2.0% to 10.0% by weight of binder, 0.1% to 3.0% by weight of lubricant, 0.1% to 3.0% by weight of anti- adherant and 2.0% to 8.0% by weight of coating agents.
  • the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 20.0% to 60.% by weight of guar gum, 20.0% to 60.0% by weight of dicalcium phosphate dihydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 8.0% by weight of coating agents.
  • the process for preparation of Trimetazidine sustained release compositions comprises the steps of: i. preparing intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients and optionally one or more release modifying agents to form a granule blend; iii. lubricating the granule blend with suitable lubricants; iv. compressing the lubricated blend to form tablets; v. coating the compressed tablets with polymer based coating.
  • the process for preparation of Trimetazidine sustained release compositions comprises the steps of: i. preparing an intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients and optionally one or more release modifying agents to form a granule blend; iii. mixing the intra-granular composition with extra granular composition to form a granule blend; iv. lubricating the granule blend with suitable lubricants; v. filling the lubricated blend into hard gelatin capsules;
  • the intra-granular composition is prepared by the process comprising the steps of:
  • the process of preparation of Trimetazidine compositions comprises the steps of: i. preparing the intra-granular composition comprising multi-particulates by extrusion or spheronisation of Trimetazidine, release modulating agents and diluents; ii. mixing the intra-granular composition with extra-granular composition comprising suitable pharmaceutically acceptable excipients and optionally release modifying agents to form a granule blend; iii. further lubricating the granule blend; iv. compressing the lubricated blend into tablets; v. coating the compressed tablets.
  • the process of preparation of Trimetazidine compositions comprises the steps of: i. preparing the intra-granular composition by granulating Trimetazidine dihydrochloride with release modifying agents by hot melt granulation or by extrusion; ii. mixing the intra-granular composition with extra-granular composition comprising suitable pharmaceutically acceptable excipients to form granule blend; iii. further lubricating the granule blend; iv. compressing the lubricated blend into tablets; v. coating the compressed tablets.
  • the process of preparation of Trimetazidine compositions comprises the steps of: i. preparing an intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients to form granule blend; iii. lubricating the granule blend with lubricants; iv. compressing the lubricated blend into minitablet; v. coating the mini-tablets with/without release modifying agent and suitable pharmaceutically acceptable excipients. vi. mixing the coated mini-tablets with suitable pharmaceutical acceptable excipients and finally compressing into tablets vii. coating the compressed tablets.
  • Another embodiment of the invention is to provide a method of treating a patient suffering from angina pectoris, comprising administering to a patient in need thereof a therapeutically effective amount of sustained release pharmaceutical compositions as described herein.
  • compositions of the present invention provide a reliable in vitro- dissolution profile for sustained effect of Trimetazidine.
  • Suitable pharmaceutically acceptable excipients that can be used for formulation include, but are not limited to, diluents/fillers, binders, anti-adherants, lubricants, and the like.
  • Diluents that may be used as per the invention include, but are not limited to dihydrogen calcium phosphate, tribasic calcium phosphate, calcium carbonate, lactose, microcrystalline cellulose or mixtures thereof and are present in an amount from 10% to 70% by weight of the total composition.
  • Binders that may be used as per the invention include, but are not limited to polyvinylpyrrolidone, gelatin, polyvinyl alcohol, gum acacia and the like and is present in an amount 1.0% to 15% by weight of the total composition.
  • Solvents that may be used as per the invention include isopropyl alcohol, water or mixtures thereof in an amount sufficient to dissolve the binder.
  • Anti-adherents that may be used as per the invention include, but are not limited to colloidal silicon dioxide, talc, starch and the like and are present in an amount from 0.1% to 5.0% by weight of the total composition.
  • Lubricants that may be used as per the invention include, but are not limited to magnesium stearate, calcium stearate, zinc stearate and the like and is present in an amount from 0.1% to 5.0% by weight of the total composition.
  • Sustained release compositions prepared by the process as described herein is further film coated using any of the conventional coating techniques known in the prior art like pan coating, spray coating etc. Tablet coat of 2%-10% with respect to total weight may be employed to have desired release.
  • Functional coating may be carried out using release modifying agents (functional coating polymers) other than cellulose and/or cellulose derivatives.
  • Functional coating polymers may be selected from polymethacrylates, polyvinylacetate phthalates, polyvinyl acetate and the like.
  • Non-functional film coating may be carried out using one or more excipients selected from the group comprising film formers, opacifiers, coating agents, taste- masking agents, colouring agents, antitacking agents and the like.
  • Film formers such as hydroxypropyl cellulose or hydroxypropyl methylcellulose or the like may be used.
  • Opacifying agents that may be used include titanium dioxide, ferric oxide, sunset yellow and the like.
  • Plasticizers such as polyethylene derivatives, polyethylene glycol, propylene glycol, triethyl citrate and the like may be used.
  • Antitacking agents include talc, stearic acid, magnesium stearate, colloidal silicon dioxide and the like.
  • Excipients for non-functional film coating may be used in concentrations which are well known to a person skilled in the art. Non-functional film coating serves the purpose of taste neutralization and provides elegance to the tablets.
  • compositions of the present invention are stable physically as well as chemically at accelerated conditions of stability.
  • sustained release compositions of the present invention shows the following in- vitro drug release characteristics when tested in 0.1N HCl for the first hour and then in phosphate buffer pH 6.8; which is comparable to the dissolution profile of Vastarel tablets.
  • release modifying agent refers to formulation excipients that sustain the release of the drug from the dosage form.
  • excipients refers to a pharmaceutically acceptable ingredient that is commonly used in the pharmaceutical technology for preparing granules and/or solid oral dosage compositions.
  • tablette refers and is intended to encompass compressed pharmaceutical dosage formulations of all shapes and sizes, whether coated or uncoated.
  • Trimetazidine dihydrochloride (175 gm), lactose monohydrate (359 gm) and polyethylene oxide (Polyox WSR N303) (150 gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (30 gm) dissolved in isopropyl alcohol (675 gm). The resultant mass was dried at 60 0 C and the agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (5.5 gm) and magnesium stearate (5.5 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
  • Trimetazidine dihydrochloride (175 gm), lactose monohydrate (400.5gm) and xanthan gum (400 gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (37.5gm) dissolved in isopropyl alcohol (215 gm). Resultant mass was dried at 60 0 C and agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (6.0 gm) and magnesium stearate (6.0 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
  • Trimetazidine dihydrochloride (175 gm), dicalcium phosphate dihydrate (388 gm) and polymethacrylate (Eudragit RSPO) (150 gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (50 gm) dissolved in isopropyl alcohol (596 gm). Resultant mass was dried at 60 0 C and the agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (6.0 gm) and magnesium stearate (6.0 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
  • Trimetazidine dihydrochloride (175 gm) and dicalcium phosphate dihydrate (354gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (25 gm) dissolved in isopropyl alcohol (115 gm). Resultant mass was dried at 60 0 C and agglomerates were milled to required size. Sized granules were blended with Kollidone SR (560gm) (Kollidone SR is a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone), colloidal silicon dioxide (5.5 gm) and magnesium stearate (5.5 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
  • Trimetazidine dihydrochloride (175 gm), dicalcium phosphate dihydrate (584gm) and polyvinyl pyrrolidone (30 gm) were mixed and granulated using binder solution containing polyvinyl alcohol (250 gm) dissolved in water (475 gm). Resultant mass was dried at 60 0 C and the agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (5.5 gm) and magnesium stearate (5.5 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
  • Glyceryl monostearate (116.67 gm) was melted at 60 0 C.
  • AUCo-t Area under the plasma concentration versus time curve, from time zero to the last measurable concentration.
  • AUCo-i nf Area under the plasma concentration versus time curve, from time zero to infinity.
  • Example 1 is bio-equivalent to reference product (Vastarel) when tested in-vivo on healthy, adult, human subjects under fasted and fed conditions. Results on in-vivo study of compositions prepared according to Example 1 is as shown in Table 3. Table 3
  • Example 2 is bio-equivalent to reference product (Vastarel) when tested in-vivo on healthy, adult, human subjects under fasted and fed conditions. Results on in-vivo study of compositions prepared according to Example 2 is as shown in Table 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques à libération prolongée contenant de la trimétazidine ou un sel pharmaceutiquement acceptable de celle-ci et des agents modifiant la libération ainsi que des excipients pharmaceutiquement acceptables appropriés. Les compositions pharmaceutiques à libération prolongée selon la présente invention se caractérisent par l'absence de cellulose et/ou de dérivés de cellulose en tant qu'agents modifiant la libération.
EP08852448A 2007-08-08 2008-08-07 Compositions à libération prolongée de trimétazidine et procédé de préparation Withdrawn EP2187874A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1533MU2007 2007-08-08
PCT/IN2008/000493 WO2009066315A2 (fr) 2007-08-08 2008-08-07 Compositions à libération prolongée de trimétazidine et procédé de préparation

Publications (1)

Publication Number Publication Date
EP2187874A2 true EP2187874A2 (fr) 2010-05-26

Family

ID=40667940

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08852448A Withdrawn EP2187874A2 (fr) 2007-08-08 2008-08-07 Compositions à libération prolongée de trimétazidine et procédé de préparation

Country Status (3)

Country Link
EP (1) EP2187874A2 (fr)
BR (1) BRPI0815602A2 (fr)
WO (1) WO2009066315A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515757A (ja) * 2009-01-20 2012-07-12 マイクロ ラブス リミテッド トリメタジジンの放出調節固形薬剤組成物及びその製造方法
TR201001902A2 (tr) * 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
ES2508490T3 (es) * 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación de trimetazidina con diferentes perfiles de liberación
EP2386302A1 (fr) * 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited Forme pharmaceutique à libération prolongée de trimetazidine et ses procédés de préparation
WO2013180676A1 (fr) * 2012-05-28 2013-12-05 Mahmut Bilgic Nouvelle formulation à libération prolongée
CN105434380A (zh) * 2015-12-11 2016-03-30 南京正科医药股份有限公司 一种盐酸曲美他嗪片
CA3044270A1 (fr) 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. Utilisation de la trimetazidine dans la prevention et/ou le traitement de l'insuffisance renale aigue induite par contraste
IL283725B2 (en) 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
EP3866794B1 (fr) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Procédés de traitement de maladies rhumatismales à l'aide de composés à base de trimétazidine
EP3976101A4 (fr) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose
CN110623934B (zh) * 2019-09-26 2022-05-13 杭州百诚医药科技股份有限公司 一种盐酸曲美他嗪缓释片及其制备方法
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
CN111888476A (zh) * 2020-08-17 2020-11-06 深圳市道科思医药有限公司 盐酸曲美他嗪的改良释放药物组合物
CN112315942B (zh) * 2020-11-04 2022-08-09 南京康川济医药科技有限公司 一种盐酸曲美他嗪缓释制剂及其制备方法
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2025068837A2 (fr) * 2023-09-26 2025-04-03 Zim Laboratories Limited Nouvelle composition pharmaceutique à libération prolongée de trimétazidine ou d'un sel de celle-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE442852T1 (de) * 2000-10-05 2009-10-15 Usv Ltd Trimetazidine enthaltendes arzneimittel mit verzögerter wirkstoffabgabe und verfahren zur herstellung
FR2818549B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AVINASH D.: "Formulation and Evaluation of Sustained release Tablets of Trimetazidine Dihydrochloride using various Polymers", AAPS ANNUAL MEETING AND EXPOSITION, 31 October 2006 (2006-10-31), pages 1 - 2, XP003032101

Also Published As

Publication number Publication date
WO2009066315A3 (fr) 2009-09-24
WO2009066315A2 (fr) 2009-05-28
BRPI0815602A2 (pt) 2015-03-03

Similar Documents

Publication Publication Date Title
WO2009066315A2 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
US5814339A (en) Film coated tablet of paracetamol and domperidone
CN103550190A (zh) 含有碱性药物或其盐的基质型缓释制剂
KR20160101720A (ko) Azd9291을 포함하는 제약 조성물
EP1195160B1 (fr) Composition pharmaceutique à effet de retard contenant de la trimétazidine et procédé pour sa préparation
US8440223B2 (en) Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers
US9387166B2 (en) Controlled release oral dosage form comprising oxycodone
US20110300209A1 (en) Modified release solid pharmaceutical compositions of trimetazidine and process thereof
WO2010026467A2 (fr) Forme pharmaceutique à libération prolongée de principe actif hautement soluble
WO2008098969A1 (fr) Compositions pharmaceutiques contenant du fumarate de quetiapine
WO2010086868A1 (fr) Compositions pharmaceutiques de trimétazidine
WO2011064797A2 (fr) Compositions pharmaceutiques à libération contrôlée de galantamine
WO2009027786A2 (fr) Formes posologiques matricielles de varénicline
WO2005011666A1 (fr) Forme posologique stable de gabapentine, pour usage oral et a liberation prolongee
EP3796908B1 (fr) Formulations de propivérine à libération contrôlée
WO2006103551A1 (fr) Formulations d’oxycodone a liberation controlee
CN101090738A (zh) 含有碱性药物或其盐的基质型缓释制剂及其制备方法
US20100272794A1 (en) Pharmaceutical composition of memantine
WO2023089553A1 (fr) Formulations à libération contrôlée de flavoxate et procédé de préparation de celles-ci
AU2018301924B2 (en) Pharmaceutical compositions
EP3618814A1 (fr) Comprimés pelliculés de déférasirox
WO2025036941A1 (fr) Forme posologique pharmaceutique à administrer par voie orale permettant une libération immédiate de vidofludimus
EP3900708A1 (fr) Composition médicale à libération prolongée contenant du zaltoprofène
MX2010014153A (es) Comprimido farmaceutico de liberacion controlada para administracion oral.
WO2012053016A1 (fr) Compositions pharmaceutiques de donépézil à libération prolongée

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100304

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100929

DAX Request for extension of the european patent (deleted)
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131001